Two Sigma Advisers LP Has $41,000 Stock Holdings in Chimerix, Inc. (NASDAQ:CMRX)

Two Sigma Advisers LP trimmed its stake in Chimerix, Inc. (NASDAQ:CMRX) by 63.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,900 shares of the biopharmaceutical company’s stock after selling 20,600 shares during the quarter. Two Sigma Advisers LP’s holdings in Chimerix were worth $41,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. bought a new stake in shares of Chimerix in the 4th quarter valued at about $183,000. Rosalind Advisors Inc. bought a new stake in shares of Chimerix during the 4th quarter worth about $10,614,000. EAM Investors LLC bought a new position in Chimerix during the 4th quarter worth $786,000. Millennium Management LLC raised its stake in Chimerix by 6.8% in the 4th quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock worth $8,900,000 after purchasing an additional 161,795 shares in the last quarter. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of Chimerix in the fourth quarter valued at approximately $221,000. Institutional investors and hedge funds own 45.42% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on CMRX shares. Wall Street Zen assumed coverage on Chimerix in a research note on Sunday, May 18th. They issued a “sell” rating for the company. Wedbush restated a “neutral” rating and issued a $8.55 target price (up from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. HC Wainwright reiterated a “neutral” rating and set a $8.55 price target (down previously from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $8.50 price objective (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th.

Chimerix Price Performance

Chimerix stock opened at $8.54 on Monday. Chimerix, Inc. has a 1 year low of $0.75 and a 1 year high of $8.55. The company has a market capitalization of $801.09 million, a P/E ratio of -9.09 and a beta of -0.17. The business has a 50 day moving average of $8.54 and a 200-day moving average of $5.88.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.01. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.31 million. Equities analysts anticipate that Chimerix, Inc. will post -0.99 EPS for the current year.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.